BLFS · As filed with the SEC
Biolife Solutions income statement, by fiscal year
The statement as Biolife Solutions presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | 96,214 | 82,254 | 143,271 | 161,759 |
| Product revenue | — | 76,028 | 117,695 | 136,000 |
| Service Revenue | — | — | — | 15,308 |
| Service revenue | — | 160 | 17,551 | — |
| Rental revenue | — | 6,066 | 8,025 | 10,451 |
| Cost of revenue | 34,096 | — | — | — |
| Gross profit | 62,118 | — | — | — |
| Operating expenses: | ||||
| Product revenue | — | 24,502 | 75,751 | 88,519 |
| Service Revenue | — | — | — | 12,360 |
| Service revenue | — | 52 | 15,586 | — |
| Rental revenue | — | 4,029 | 5,182 | 7,058 |
| General and administrative | 45,520 | 40,541 | 55,725 | 47,670 |
| Sales and marketing | 9,850 | 9,610 | 24,583 | 21,570 |
| Research and development | 7,566 | 7,912 | 18,796 | 14,798 |
| Asset impairment charges | — | — | 15,485 | 110,364 |
| IPR&D expense | 15,521 | — | — | — |
| Intangible asset amortization | 263 | 2,737 | 5,181 | 9,697 |
| Acquisition costs | — | — | 0 | 18 |
| Change in fair value of contingent consideration | 0 | 0 | (2,193) | (4,754) |
| Total operating expenses | 78,720 | 89,383 | 214,096 | 307,300 |
| Operating loss | (16,602) | (7,129) | (70,825) | (145,541) |
| Other income (expense): | ||||
| Change in fair value of warrant liability | — | — | 0 | 0 |
| Interest income (expense), net | 2,706 | (719) | (1,812) | (687) |
| Other income | 1,815 | 497 | 1,264 | 704 |
| Change in fair value of investments | 0 | (4,074) | 0 | 697 |
| Gain on settlement of Global Cooling escrow | 0 | 0 | 5,115 | — |
| Gain on acquisition of Sexton Biotechnologies, Inc. | — | — | 0 | 0 |
| Total other income (expense), net | 4,521 | (4,296) | 4,567 | 714 |
| Loss from continuing operations before income tax expense (benefit) | (12,081) | (11,425) | (66,258) | (144,827) |
| Income tax expense (benefit) | 49 | 38 | (169) | 5,022 |
| Loss from continuing operations | (12,130) | (11,387) | — | — |
| Discontinued operations: | ||||
| Income (loss) from discontinued operations before income tax expense | 7,535 | (8,665) | — | — |
| Income tax expense | 0 | (132) | — | — |
| Income (loss) from discontinued operations | 7,535 | (8,797) | — | — |
| Net loss | (4,595) | (20,184) | (66,427) | (139,805) |
| Net loss attributable to common shareholders, basic | — | — | (66,427) | (139,805) |
| Net loss attributable to common shareholders, diluted | — | — | (66,427) | (139,805) |
| Loss per share - Basic: | ||||
| Continuing operations (in dollars per share) | (0.25) | (0.25) | — | — |
| Discontinuing operations (in dollars per share) | 0.16 | (0.19) | — | — |
| Net loss (in dollars per share) | (0.09) | (0.44) | (1.52) | (3.29) |
| Loss per share - Diluted: | ||||
| Continuing operations (in dollars per share) | (0.25) | (0.25) | — | — |
| Discontinuing operations (in dollars per share) | 0.15 | (0.19) | — | — |
| Net loss (in dollars per share) | (0.10) | (0.44) | (1.52) | (3.29) |
| Weighted average shares used to compute net loss per share attributable to common shareholders: | ||||
| Basic (in shares) | 47,753,824 | 46,067,073 | 43,719,185 | 42,481,027 |
| Diluted (in shares) | 48,645,084 | 46,067,073 | 43,719,185 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.